Do you have a new diagnosis of Acute Myeloid Leukemia and are looking for another treatment option? In this study, we are looking to see if the study drug (Tagraxofusp) can help control Leukemia or achieve remission.

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment.

Have you been diagnosed with unfavorable risk prostate cancer? Are you looking for treatment options? If so, you may be able to participate in a clinical trial examining different treatment options for prostate cancer.

Researchers at the University of North Carolina at Chapel Hill are studying innovative ways to promote healthy eating, physical activity, and weight loss in young adults using a smartphone app, digital health tools, and daily messaging. We are seeking volunteers to enroll in a 6-month research study that tests a smartphone-delivered weight loss program designed specifically for young adults.

Have you been recently diagnosed with Acute Lymphoblastic Leukemia? If so, you may be able to take part in a research study to help us learn more about the effects of using Tyrosine Kinase Inhibitor (TKI), steroids and blinatumomab versus treatment with steroids, Tyrosine Kinase Inhibitor (TKI) and chemotherapy.

To evaluate the safety and efficacy of BLU-222 therapy in patients with advanced solid tumors.

This is a study to learn more about the safety and effectiveness of PT217 to treat advanced cancers. We are looking for patients with small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer or gastroenteropancreatic neuroendocrine carcinomas to take part.

Have you been diagnosed with Advanced Renal Cell Carcinoma? If so, you may be able to take part in a research study investigating the optimal way to combine or sequence therapies in patients with renal cell cancer with bone metastasis.

Do you have locally advanced, inoperable, node-positive non-small cell lung cancer (NSCLC), stage II or III? If so, you may be able to take part in a study to learn more about the effectiveness of adding stereotactic body radiation therapy (SBRT) to the standard treatment of radiation and chemotherapy.

To get a number reading of a CD3+/CD8+ T cell Breast Immunoscore using immunofluorescence (QIF) in posttreatment FFPE tumor biopsy samples collected on day 14-21 of C1 of Pembrolizumab.